ArticleFrontiers in immunology2026

Targeting CD39 in combination with IL-2/anti-IL-2 complexes enhances cytotoxic immunity and limits tumor progression.

Carolina Abrate et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.